These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28447277)

  • 1. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
    Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
    J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
    Bloch O; Lim M; Sughrue ME; Komotar RJ; Abrahams JM; O'Rourke DM; D'Ambrosio A; Bruce JN; Parsa AT
    Clin Cancer Res; 2017 Jul; 23(14):3575-3584. PubMed ID: 28193626
    [No Abstract]   [Full Text] [Related]  

  • 3. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
    Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
    Front Immunol; 2020; 11():580335. PubMed ID: 33224142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1/PD-1 Axis in Glioblastoma Multiforme.
    Litak J; Mazurek M; Grochowski C; Kamieniak P; Roliński J
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma.
    Çakır E; Saygın İ; Ercin ME
    Turk J Med Sci; 2021 Aug; 51(4):1800-1808. PubMed ID: 33600097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
    Yao Y; Luo F; Tang C; Chen D; Qin Z; Hua W; Xu M; Zhong P; Yu S; Chen D; Ding X; Zhang Y; Zheng X; Yang J; Qian J; Deng Y; Hoon DSB; Hu J; Chu Y; Zhou L
    Cancer Immunol Immunother; 2018 Nov; 67(11):1777-1788. PubMed ID: 30159779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.
    Tamura R; Tanaka T; Ohara K; Miyake K; Morimoto Y; Yamamoto Y; Kanai R; Akasaki Y; Murayama Y; Tamiya T; Yoshida K; Sasaki H
    Cancer Sci; 2019 Feb; 110(2):499-508. PubMed ID: 30467920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
    Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
    Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated microenvironment, PD-L1 expression and their relationship with immunotherapy in glioblastoma, IDH-wild type: A comprehensive review with emphasis on the implications for neuropathologists.
    Broggi G; Angelico G; Farina J; Tinnirello G; Barresi V; Zanelli M; Palicelli A; Certo F; Barbagallo G; Magro G; Caltabiano R
    Pathol Res Pract; 2024 Feb; 254():155144. PubMed ID: 38277747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.
    Ahn J; Bishop JA; Roden RBS; Allen CT; Best SRA
    Laryngoscope; 2018 Jan; 128(1):E27-E32. PubMed ID: 28940446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma.
    Kuang RZ; Wang J; Wang YC; Tang XP
    Clinics (Sao Paulo); 2024; 79():100376. PubMed ID: 38733690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint-Blocking Nanocages Cross the Blood-Brain Barrier and Impede Brain Tumor Growth.
    Kim M; Yoon HJ; Lee C; Lee M; Park RW; Lee B; Park EJ; Kim S
    ACS Biomater Sci Eng; 2024 Jan; 10(1):575-587. PubMed ID: 38150627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma.
    Nguyen TTT; Gao Q; Mun JY; Zhu Z; Shu C; Naim A; Rogava M; Izar B; Westhoff MA; Karpel-Massler G; Siegelin MD
    Cells; 2024 Jul; 13(13):. PubMed ID: 38995006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial neural network identified a 20-gene panel in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in glioblastoma patients.
    Wang Y; Wang Z; Guo X; Cao Y; Xing H; Wang Y; Xing B; Wang Y; Yao Y; Ma W
    Cancer Med; 2024 May; 13(9):e7218. PubMed ID: 38733169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling of Tumor-Infiltrating Immune Cells and Their Impact on Survival in Glioblastoma Patients Undergoing Immunotherapy with Dendritic Cells.
    Peres N; Lepski GA; Fogolin CS; Evangelista GCM; Flatow EA; de Oliveira JV; Pinho MP; Bergami-Santos PC; Barbuto JAM
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M-MDSCs mediated trans-BBB drug delivery for suppression of glioblastoma recurrence post-standard treatment.
    Yu T; Wang K; Wang J; Liu Y; Meng T; Hu F; Yuan H
    J Control Release; 2024 May; 369():199-214. PubMed ID: 38537717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
    Khasraw M; Reardon DA; Weller M; Sampson JH
    Clin Cancer Res; 2020 Oct; 26(20):5287-5296. PubMed ID: 32527943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma.
    Chen L; Liu H; Li Y; Lin X; Xia S; Wanggou S; Li X
    Front Immunol; 2023; 14():1105489. PubMed ID: 36845098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice.
    Zhao K; Calero-Pérez P; Bopp MHA; Möschl V; Pagenstecher A; Mulero-Acevedo M; Vázquez M; Barcia C; Arús C; Nimsky C; Rusch T; Bartsch JW; Candiota AP
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas.
    Muragaki Y; Ishikawa E; Maruyama T; Nitta M; Saito T; Ikuta S; Komori T; Kawamata T; Yamamoto T; Tsuboi K; Matsumura A; Nakamura H; Kuroda J; Abe T; Momii Y; Saito R; Tominaga T; Tabei Y; Suzuki I; Arakawa Y; Miyamoto S; Matsutani M; Karasawa K; Nakazato Y; Maebayashi K; Hashimoto K; Ohno T
    J Neurosurg; 2023 Aug; 139(2):344-354. PubMed ID: 36670529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.